ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 092,11
-0,61%
Dow Jones
39 721,70
-0,38%
DAX
18 680,20
-0,25%
Brent Oil
81,655
-0,96%
Bitcoin
69 828,08
-0,43%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Deciphera Pharmaceuticals Inc (DCPH)

  7. Deciphera Pharmaceuticals Inc (DCPH) Actualités

DCPH

Deciphera Pharmaceuticals (DCPH)

Deciphera Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:DCPH
DateHeureSourceTitreSymboleSociété
22/05/202415h06Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:DCPHDeciphera Pharmaceuticals Inc
22/05/202413h01Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:DCPHDeciphera Pharmaceuticals Inc
13/05/202412h32Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:DCPHDeciphera Pharmaceuticals Inc
13/05/202412h31Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:DCPHDeciphera Pharmaceuticals Inc
10/05/202413h27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DCPHDeciphera Pharmaceuticals Inc
06/05/202423h16Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:DCPHDeciphera Pharmaceuticals Inc
29/04/202413h00Business WireDeciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 BillionNASDAQ:DCPHDeciphera Pharmaceuticals Inc
09/04/202413h00Business WireDeciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology ForumNASDAQ:DCPHDeciphera Pharmaceuticals Inc
27/02/202413h00Business WireDeciphera Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:DCPHDeciphera Pharmaceuticals Inc
20/02/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DCPHDeciphera Pharmaceuticals Inc
14/02/202422h06Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:DCPHDeciphera Pharmaceuticals Inc
07/02/202413h52Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:DCPHDeciphera Pharmaceuticals Inc
07/02/202413h11Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:DCPHDeciphera Pharmaceuticals Inc
06/02/202413h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DCPHDeciphera Pharmaceuticals Inc
06/02/202413h00Business WireDeciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:DCPHDeciphera Pharmaceuticals Inc
01/02/202422h50Business WireDeciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024NASDAQ:DCPHDeciphera Pharmaceuticals Inc
01/02/202413h00Business WireDeciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:DCPHDeciphera Pharmaceuticals Inc
18/01/202417h13Business WireDeciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers SymposiumNASDAQ:DCPHDeciphera Pharmaceuticals Inc
08/01/202413h00Business WireDeciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product CompanyNASDAQ:DCPHDeciphera Pharmaceuticals Inc
05/01/202413h00Business WireDeciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18NASDAQ:DCPHDeciphera Pharmaceuticals Inc
02/01/202413h00Business WireDeciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:DCPHDeciphera Pharmaceuticals Inc
01/12/202300h05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DCPHDeciphera Pharmaceuticals Inc
29/11/202313h00Business WireDeciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology SummitNASDAQ:DCPHDeciphera Pharmaceuticals Inc
30/10/202312h01Business WireDeciphera Pharmaceuticals Announces Third Quarter 2023 Financial ResultsNASDAQ:DCPHDeciphera Pharmaceuticals Inc
30/10/202312h00Business WireDeciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCTNASDAQ:DCPHDeciphera Pharmaceuticals Inc
29/09/202315h00PR Newswire (US)Medison Pharma Announces Public Formulary Listing of QINLOCK® (ripretinib) in Canadian Provinces: Ontario and Quebec for Advanced Gastrointestinal Stromal Tumor (GIST) TreatmentNASDAQ:DCPHDeciphera Pharmaceuticals Inc
15/09/202323h00Business WireDeciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:DCPHDeciphera Pharmaceuticals Inc
05/09/202322h15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:DCPHDeciphera Pharmaceuticals Inc
09/08/202313h00Business WireDeciphera Pharmaceuticals Announces Second Quarter 2023 Financial ResultsNASDAQ:DCPHDeciphera Pharmaceuticals Inc
03/08/202322h15Business WireDeciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific OfficerNASDAQ:DCPHDeciphera Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:DCPH

Dernières Valeurs Consultées

AMEX
SCHG
Schwab US Large Cap Growth
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés